Lutfu Askin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lutfu Askin has a total of 248 co-authors. Here are the top co-authors by number of shared publications:
Okan Tanriverdi
Department of Cardiology Adiyaman Education and Research Hospital Adiyaman Turkey
13 shared publicationsSerdar Turkmen
Adiyaman University Education and Research Hospital - Cardiology,Adıyaman, Century - Turquia
9 shared publicationsOkan Tanrıverdi
Clinic of Cardiology Adıyaman Traninig and Research Hospital Adıyaman Türkiye
7 shared publicationsMustafa Cetin
Sanko University - Cardiology, Gaziantep - Turquia
4 shared publications- Okan Tanriverdi
Siirt University
4 shared publications Erdal Akturk
Department of cardiology, Adiyaman Education and Research Hospital, Adiyaman, Turkey
3 shared publications
Latest Publications
- Open Access
- 6 May 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25
Efficacy and safety of combination therapy with statin and ezetimibe in patients failing to achieve target LDL levels at cardiology outpatient clinics in Turkey (COM-TR-OLDL): a real-world observational study
Background: Achieving target low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease (ASCVD) frequently requires combination lipid-lowering therapy. Single-pill combination (SPC) regimens may improve adherence compared with free-dose combinations (FDC) in real-world clinical practice. Methods: This retrospective observational study included 450 ASCVD patients with baseline LDL-C levels of 70–189 mg/dL who were followed in cardiology outpatient clinics between January 2023 and December 2024. Patients received atorvastatin–ezetimibe either as a single-pill combination (SPC, n = 392) or as a free-dose combination (FDC, n = 58). Primary endpoints were LDL-C reduction and treatment adherence (≥ 80% of prescribed doses). Secondary endpoints included LDL-C target attainment and adverse events. Non-parametric tests and chi-square/Fisher’s exact tests were used for statistical analysis. Results: At 1 month, LDL-C levels were significantly lower in the SPC group compared with the FDC group (90.6 vs. 119 mg/dL; p = 0.005), and adherence was higher (89.8% vs. 70.7%; p < 0.001). At 4 months, LDL-C levels were comparable between groups, while continuous adherence remained significantly higher in the SPC group (86% vs. 69%; p = 0.001). A higher proportion of SPC-treated patients achieved LDL-C < 100 mg/dL at 1 month (81.9% vs. 67.2%; p = 0.009). Conclusions: In this real-world ASCVD cohort, SPC therapy with atorvastatin and ezetimibe was associated with superior adherence and comparable lipid-lowering efficacy despite lower statin doses. Fixed-dose combination strategies may represent an effective approach to optimize adherence and cardiovascular risk management.
- 6 May 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25
Open AccessEfficacy and safety of combination therapy with statin and ezetimibe in patients failing to achieve target LDL levels at cardiology outpatient clinics in Turkey (COM-TR-OLDL): a real-world observational study
Background: Achieving target low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease (ASCVD) frequently requires combination lipid-lowering therapy. Single-pill combination (SPC) regimens may improve adherence compared with free-dose combinations (FDC) in real-world clinical practice. Methods: This retrospective observational study included 450 ASCVD patients with baseline LDL-C levels of 70–189 mg/dL who were followed in cardiology outpatient clinics between January 2023 and December 2024. Patients received atorvastatin–ezetimibe either as a single-pill combination (SPC, n = 392) or as a free-dose combination (FDC, n = 58). Primary endpoints were LDL-C reduction and treatment adherence (≥ 80% of prescribed doses). Secondary endpoints included LDL-C target attainment and adverse events. Non-parametric tests and chi-square/Fisher’s exact tests were used for statistical analysis. Results: At 1 month, LDL-C levels were significantly lower in the SPC group compared with the FDC group (90.6 vs. 119 mg/dL; p = 0.005), and adherence was higher (89.8% vs. 70.7%; p < 0.001). At 4 months, LDL-C levels were comparable between groups, while continuous adherence remained significantly higher in the SPC group (86% vs. 69%; p = 0.001). A higher proportion of SPC-treated patients achieved LDL-C < 100 mg/dL at 1 month (81.9% vs. 67.2%; p = 0.009). Conclusions: In this real-world ASCVD cohort, SPC therapy with atorvastatin and ezetimibe was associated with superior adherence and comparable lipid-lowering efficacy despite lower statin doses. Fixed-dose combination strategies may represent an effective approach to optimize adherence and cardiovascular risk management.
- Open Access
- 6 November 2025
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 67 (5) , 641-645
The LACE Index: A Predictor of Mortality and Readmission in Cardiovascular Diseases
Index LACE je predik?n? n?stroj pou??van? ve zdravotnictv? pro odhad rizika op?tovn? hospitalizace pacient? po jejich propu?t?n? z nemocnice. Zkratka LACE vznikla spojen?m slov (v angli?tin?) d?lka pobytu v nemocnici (length of stay), opr?vn?n...
- 6 November 2025
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 67 (5) , 641-645
Open AccessThe LACE Index: A Predictor of Mortality and Readmission in Cardiovascular Diseases
Index LACE je predik?n? n?stroj pou??van? ve zdravotnictv? pro odhad rizika op?tovn? hospitalizace pacient? po jejich propu?t?n? z nemocnice. Zkratka LACE vznikla spojen?m slov (v angli?tin?) d?lka pobytu v nemocnici (length of stay), opr?vn?n...
- Open Access
- 6 October 2025
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 67 (4) , 505-509
Controlling Nutritional Status Score is Linked to Cardiovascular Diseases
Zv??en? hodnota sk?re CONUT (Controlling Nutritional Status) byla ji? d??ve d?na do souvislosti s vy???m rizikem rozvoje kardiovaskul?rn?ch onemocn?n? (KVO), jako jsou ischemick? choroba srde?n?, c?vn? mozkov? p??hoda a srde?n? selh?n?. Nedost...
- 6 October 2025
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 67 (4) , 505-509
Open AccessControlling Nutritional Status Score is Linked to Cardiovascular Diseases
Zv??en? hodnota sk?re CONUT (Controlling Nutritional Status) byla ji? d??ve d?na do souvislosti s vy???m rizikem rozvoje kardiovaskul?rn?ch onemocn?n? (KVO), jako jsou ischemick? choroba srde?n?, c?vn? mozkov? p??hoda a srde?n? selh?n?. Nedost...
- Open Access
- 9 April 2025
- Published by Galenos Yayinevi in Interventional Cardiology Perspectives
- Vol. 1 (1) , 1-5
Oncostatin M and Cardiovascular Diseases: A Narrative Review
Oncostatin M and Cardiovascular Diseases: A Narrative Review - Interventional Cardiology Perspectives
- 9 April 2025
- Published by Galenos Yayinevi in Interventional Cardiology Perspectives
- Vol. 1 (1) , 1-5
Open AccessOncostatin M and Cardiovascular Diseases: A Narrative Review
Oncostatin M and Cardiovascular Diseases: A Narrative Review - Interventional Cardiology Perspectives
- Open Access
- 20 December 2024
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 66 (6) , 608-614
Serum Paraoxonase-1 and Atherosclerotic Cardiovascular Disease
D?ky sv?mu um?st?n? chr?n? hydrofobn? lipidov? dom?na paraoxon?zy-1 (PON-1) lipoproteiny o vysok? hustot? (high-density lipoprotein, HDL), lipoproteiny o n?zk? hustot? (low-density lipoprotein, LDL) a bun??n? membr?ny na vn?j?? stran? p?ed oxi...
- 20 December 2024
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 66 (6) , 608-614
Open AccessSerum Paraoxonase-1 and Atherosclerotic Cardiovascular Disease
D?ky sv?mu um?st?n? chr?n? hydrofobn? lipidov? dom?na paraoxon?zy-1 (PON-1) lipoproteiny o vysok? hustot? (high-density lipoprotein, HDL), lipoproteiny o n?zk? hustot? (low-density lipoprotein, LDL) a bun??n? membr?ny na vn?j?? stran? p?ed oxi...
- Open Access
- 30 September 2024
- Published by Gaziantep Islam Science and Technology University in Experimental and Applied Medical Science
- Vol. 5 (4) , 168-181
Exploring the Potential of Artificial Intelligence in Infectious Disease
Artificial intelligence (AI) addressed several infectious disease concerns by using its capabilities and acknowledging its constraints, with some adjustments and clarifications. The research focused on important difficulties related to artificial intelligence in infectious diseases. This review advocates for the use of artificial intelligence in infectious disease clinical practice and research. AI categorises article components such as title, abstract, introduction, method, findings, and discussions, which helps scholars save time. This speeds up and improves scientific writing. Some comments may be misleading or inaccurate, putting the accuracy of the research at risk. Current AI systems provide precise and safe responses, but they often lack contextual understanding. The lack of diagnostic technologies in artificial intelligence leads to misidentification and safety risks. Utilising medical technology ethically requires supervision and regulation. Some institutions have prohibited AI research because of its inefficacy. AI may assist physicians by gathering medical data and patient case studies. Identify and control new technologies. ChatGPT and other medical AI models need more data for training.
- 30 September 2024
- Published by Gaziantep Islam Science and Technology University in Experimental and Applied Medical Science
- Vol. 5 (4) , 168-181
Open AccessExploring the Potential of Artificial Intelligence in Infectious Disease
Artificial intelligence (AI) addressed several infectious disease concerns by using its capabilities and acknowledging its constraints, with some adjustments and clarifications. The research focused on important difficulties related to artificial intelligence in infectious diseases. This review advocates for the use of artificial intelligence in infectious disease clinical practice and research. AI categorises article components such as title, abstract, introduction, method, findings, and discussions, which helps scholars save time. This speeds up and improves scientific writing. Some comments may be misleading or inaccurate, putting the accuracy of the research at risk. Current AI systems provide precise and safe responses, but they often lack contextual understanding. The lack of diagnostic technologies in artificial intelligence leads to misidentification and safety risks. Utilising medical technology ethically requires supervision and regulation. Some institutions have prohibited AI research because of its inefficacy. AI may assist physicians by gathering medical data and patient case studies. Identify and control new technologies. ChatGPT and other medical AI models need more data for training.
- 6 August 2024
- Published by Academician Publishing
- p. 151-160
Kardiyak Resenkronizasyon Tedavisi Yanıt Tanımı ve İlişkili Faktörler
- 6 August 2024
- Published by Academician Publishing
- p. 151-160
Kardiyak Resenkronizasyon Tedavisi Yanıt Tanımı ve İlişkili Faktörler
- Open Access
- 6 August 2024
- Published by Academician Publishing
İmplante Edilebilir Kardiyak Elektronik Cihazlar
Kardiyak Pace Tipi ve Pacing Modları Gamze Yeter ARSLAN Kalıcı Kalp Pili Endikasyonları Yusuf HOŞOĞLU Ayşe HOŞOĞLU Pacemaker & ICD İmplantasyonu Yakup YİĞİT Leadless Pacemaker Yusuf Ziya ŞENER Geçici Transvenöz Pacing ve Komplikasyonları Didar Elif AKGUN Yavuz Selim AKGUN Primer Koruma Amaçlı İmplante Edilebilir Kardiyoverter Defibrilatör Tarık YILDIRIM Sekonder Profilaksi Amaçlı İmplante Edilebilir Kardiyoverter Defibrilatör Seda Elçim YILDIRIM İmplante Edilebilir Kardiyoverter-Defibrilatör Programlama Arzu YAZAR İmplante Edilebilir Kardiyoverter Defibrilatör (ICD) Mevcut Hastalarda Uygun Cihaz Şoklarının Yönetimi Neşri DANIŞMAN Şeyhmus KULAHCIOĞLU Uygunsuz İmplante Edilebilir Kardiyoverter Defibrilatör (ICD) Şokları ve Yönetimi Onur ALTINKAYA Subkutan ICD Ertan AYDIN Giyilebilir Kardiyak Defibrilatör Abdullah SARIHAN Lütfü BEKAR Genetik Testler Selahattin AKYOL Holter Ritim Monitörizasyonu Sinem ÖZBAY ÖZYILMAZ İmplante Edilebilir Loop Recorder Hatice TAŞKAN Tilt Table Testi Güney SARIOĞLU Pacemaker ve ICD Endikasyonu Belirlemede Kullanılan Testler-Kardiyak Görüntüleme (EKO ve MRG) Emirhan ÇAKIR Elektrofizyolojik Çalışma Muhammed Kemal KAHYALAR Kalp Yetersizliği Tedavisinde Kardiyak Resenkronizasyon Tedavisi Enfal ÇAKMAK AKSU Fatih AKKAYA Kardiyak Resenkronizasyon Tedavisi Endikasyonları ve Hasta Seçimi Tayfur ERDOĞDU Koroner Sinüs Anatomisi ve KRT Doğan İLİŞ KRT İmplantasyonu Kubilay ERSELCAN Cerrahi KRT İmplantasyonu Mahmut YARGI Kime KRT-D & Kime KRT-P Fahri CAKAN Kardiyak Resenkronizasyon Tedavisi Yanıt Tanımı ve İlişkili Faktörler Lütfü AŞKIN Elektrokardiyografi ve Ekokardiyografi ile Kardiyak Resenkronizasyon Tedavisi Optimizasyonu Şerif HAMİDEYİN Kardiyak Resenkronizasyon Tedavisi Programlama Fatih KÖKSAL Diyafragma Pacingi Yönetimi Emre ASİLTÜRK Atriyal Fibrilasyonda Atrioventriküler (AV) Nod Ablasyonu ve Kardiyak Resenkronizasyon Tedavisi Halil İbrahim DURMUŞ HİS-Demeti Pacing Ayça ARSLAN Sol Dal Pacing İnanç ARTAÇ HİS Optimize Kardiyak Resenkranizasyon Tedavisi Süleyman BARUTCU Sol Dal Optimize Kardiyak Resenkronizasyon Tedavisi Hakan Gökalp UZUN Jeneratör Replasmanı Yusuf Bozkurt ŞAHİN Lead Ekstraksiyonu Nihan BAHADIR Kardiyak İmplante Edilebilir Elektronik Cihazların (KİEC) İmplantasyonu Sonrası Takip Şeyhmus Erkan DEMİRCAN Baver EKİNCİ Atrial Yüksek Hız Epizot Yönetimi Muhammet GENEŞ Kardiyak İmplante Edilebilir Cihazlarda Telekardiyografik Değerlendirme Zelal TAHAOĞLU Pil Cebi Hematomu Sidar Şiyar AYDIN Pnömotoraks, Hemotoraks ve Brakiyal Pleksus Yaralanması Ali Nail KAYA Kardiyak İmplante Edilebilir Elektronik Cihazların Komplikasyonu Kardiyak Rüptür/Perikardiyal Efüzyon Burcu KODAL Lead Kusurları Mert Pehlivan ALTIN Lead Dislokasyonu Sendromları Vedat CİCEK Samet YAVUZ Lead İlişkili Triküspit Yetmezliği Timor OMAR Pacemaker Aracılı Taşikardi Lütfullah CANDAN Pacemaker Sendromu Murat KARACAM Gülümser Sevgin HALİL Oversense Sendromları Selahattin AYDIN Kardiyak İmplante Edilebilir Cihaz Enfeksiyonu Mürsel ŞAHİN Kiec İlişkili Lead Trombüsü ve Pulmoner Embolizm Emre YILMAZ Karotid Baroreseptör Stimülasyonu Fehmi ESER Ramazan DUZ Kardiyak Kontraktilite Modülasyonu Sümeyye Fatma ÖZER Pulmoner Arter Basıncı Monitorizasyonu Muammer KARAKAYALI Kardiyak İmplante Edilebilir Elektronik Cihaz İmplantasyon Sürecinde Antikoagülan Tedavi ve Antibiyotik Proflaksisi Ömer ŞİT Preoperatif Kardiyak İmplante Edilebilen Cihaz Ayarlama Ferit BÖYÜK Radyoterapi Sürecinde Kalp Pili & ICD Takibi Yusuf Ziya ŞENER Kardiyak İmplante Edilebilir Elektronik Cihazı Olan Hastada Manyetik Rezonans Görüntüleme Semih KALKAN Kalp Pili & İmplante Edilebilir Kardiyak Defibrilatör (ICD) Olan Hastalarda Spor Aktivitesi ve Sürücülük Ahmet Lütfü SERTDEMİR Ahmet Taha ŞAHİN LVAD İmplantasyonu Yapılan Hastada ICD Endikasyonu ve Yönetimi Berhan KESKİN Kardiyak Cerrahi Sonrası Pacing Muhammed Bahadır OMAR TAVİ Sonrası Pacemaker İmplantasyonu Mehmet KIŞ Çisem OKTAY Konjenital Kalp Hastalıklarında Kardiyak Pacing ve ICD Mücahit TAN Naci BABAT Sarkoidoz Kardiyak Pacing ve ICD Ercan CEĞİLLİ Pakize SUCU Kardiyak Amiloidozda Kardiyak Pacing ve ICD Onur ASLAN Hipertrofik Kardiyomiyopatide Kardiyak Pacing ve ICD Burcu OZYAZGAN Nadir Kardiyak Hastalıklarda Kardiyak Pacing ve ICD Songül USALP
- 6 August 2024
- Published by Academician Publishing
Open Accessİmplante Edilebilir Kardiyak Elektronik Cihazlar
Kardiyak Pace Tipi ve Pacing Modları Gamze Yeter ARSLAN Kalıcı Kalp Pili Endikasyonları Yusuf HOŞOĞLU Ayşe HOŞOĞLU Pacemaker & ICD İmplantasyonu Yakup YİĞİT Leadless Pacemaker Yusuf Ziya ŞENER Geçici Transvenöz Pacing ve Komplikasyonları Didar Elif AKGUN Yavuz Selim AKGUN Primer Koruma Amaçlı İmplante Edilebilir Kardiyoverter Defibrilatör Tarık YILDIRIM Sekonder Profilaksi Amaçlı İmplante Edilebilir Kardiyoverter Defibrilatör Seda Elçim YILDIRIM İmplante Edilebilir Kardiyoverter-Defibrilatör Programlama Arzu YAZAR İmplante Edilebilir Kardiyoverter Defibrilatör (ICD) Mevcut Hastalarda Uygun Cihaz Şoklarının Yönetimi Neşri DANIŞMAN Şeyhmus KULAHCIOĞLU Uygunsuz İmplante Edilebilir Kardiyoverter Defibrilatör (ICD) Şokları ve Yönetimi Onur ALTINKAYA Subkutan ICD Ertan AYDIN Giyilebilir Kardiyak Defibrilatör Abdullah SARIHAN Lütfü BEKAR Genetik Testler Selahattin AKYOL Holter Ritim Monitörizasyonu Sinem ÖZBAY ÖZYILMAZ İmplante Edilebilir Loop Recorder Hatice TAŞKAN Tilt Table Testi Güney SARIOĞLU Pacemaker ve ICD Endikasyonu Belirlemede Kullanılan Testler-Kardiyak Görüntüleme (EKO ve MRG) Emirhan ÇAKIR Elektrofizyolojik Çalışma Muhammed Kemal KAHYALAR Kalp Yetersizliği Tedavisinde Kardiyak Resenkronizasyon Tedavisi Enfal ÇAKMAK AKSU Fatih AKKAYA Kardiyak Resenkronizasyon Tedavisi Endikasyonları ve Hasta Seçimi Tayfur ERDOĞDU Koroner Sinüs Anatomisi ve KRT Doğan İLİŞ KRT İmplantasyonu Kubilay ERSELCAN Cerrahi KRT İmplantasyonu Mahmut YARGI Kime KRT-D & Kime KRT-P Fahri CAKAN Kardiyak Resenkronizasyon Tedavisi Yanıt Tanımı ve İlişkili Faktörler Lütfü AŞKIN Elektrokardiyografi ve Ekokardiyografi ile Kardiyak Resenkronizasyon Tedavisi Optimizasyonu Şerif HAMİDEYİN Kardiyak Resenkronizasyon Tedavisi Programlama Fatih KÖKSAL Diyafragma Pacingi Yönetimi Emre ASİLTÜRK Atriyal Fibrilasyonda Atrioventriküler (AV) Nod Ablasyonu ve Kardiyak Resenkronizasyon Tedavisi Halil İbrahim DURMUŞ HİS-Demeti Pacing Ayça ARSLAN Sol Dal Pacing İnanç ARTAÇ HİS Optimize Kardiyak Resenkranizasyon Tedavisi Süleyman BARUTCU Sol Dal Optimize Kardiyak Resenkronizasyon Tedavisi Hakan Gökalp UZUN Jeneratör Replasmanı Yusuf Bozkurt ŞAHİN Lead Ekstraksiyonu Nihan BAHADIR Kardiyak İmplante Edilebilir Elektronik Cihazların (KİEC) İmplantasyonu Sonrası Takip Şeyhmus Erkan DEMİRCAN Baver EKİNCİ Atrial Yüksek Hız Epizot Yönetimi Muhammet GENEŞ Kardiyak İmplante Edilebilir Cihazlarda Telekardiyografik Değerlendirme Zelal TAHAOĞLU Pil Cebi Hematomu Sidar Şiyar AYDIN Pnömotoraks, Hemotoraks ve Brakiyal Pleksus Yaralanması Ali Nail KAYA Kardiyak İmplante Edilebilir Elektronik Cihazların Komplikasyonu Kardiyak Rüptür/Perikardiyal Efüzyon Burcu KODAL Lead Kusurları Mert Pehlivan ALTIN Lead Dislokasyonu Sendromları Vedat CİCEK Samet YAVUZ Lead İlişkili Triküspit Yetmezliği Timor OMAR Pacemaker Aracılı Taşikardi Lütfullah CANDAN Pacemaker Sendromu Murat KARACAM Gülümser Sevgin HALİL Oversense Sendromları Selahattin AYDIN Kardiyak İmplante Edilebilir Cihaz Enfeksiyonu Mürsel ŞAHİN Kiec İlişkili Lead Trombüsü ve Pulmoner Embolizm Emre YILMAZ Karotid Baroreseptör Stimülasyonu Fehmi ESER Ramazan DUZ Kardiyak Kontraktilite Modülasyonu Sümeyye Fatma ÖZER Pulmoner Arter Basıncı Monitorizasyonu Muammer KARAKAYALI Kardiyak İmplante Edilebilir Elektronik Cihaz İmplantasyon Sürecinde Antikoagülan Tedavi ve Antibiyotik Proflaksisi Ömer ŞİT Preoperatif Kardiyak İmplante Edilebilen Cihaz Ayarlama Ferit BÖYÜK Radyoterapi Sürecinde Kalp Pili & ICD Takibi Yusuf Ziya ŞENER Kardiyak İmplante Edilebilir Elektronik Cihazı Olan Hastada Manyetik Rezonans Görüntüleme Semih KALKAN Kalp Pili & İmplante Edilebilir Kardiyak Defibrilatör (ICD) Olan Hastalarda Spor Aktivitesi ve Sürücülük Ahmet Lütfü SERTDEMİR Ahmet Taha ŞAHİN LVAD İmplantasyonu Yapılan Hastada ICD Endikasyonu ve Yönetimi Berhan KESKİN Kardiyak Cerrahi Sonrası Pacing Muhammed Bahadır OMAR TAVİ Sonrası Pacemaker İmplantasyonu Mehmet KIŞ Çisem OKTAY Konjenital Kalp Hastalıklarında Kardiyak Pacing ve ICD Mücahit TAN Naci BABAT Sarkoidoz Kardiyak Pacing ve ICD Ercan CEĞİLLİ Pakize SUCU Kardiyak Amiloidozda Kardiyak Pacing ve ICD Onur ASLAN Hipertrofik Kardiyomiyopatide Kardiyak Pacing ve ICD Burcu OZYAZGAN Nadir Kardiyak Hastalıklarda Kardiyak Pacing ve ICD Songül USALP
- 17 June 2024
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 79 (6) , 699-704
Association of high-sensitivity troponin T with left ventricular dysfunction in prediabetes
Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are an increasingly serious problem worldwide. Tissue Doppler imaging (TDI), a non-invasive technique, may evaluate both systolic and diastolic function during the first phases of cardiovascular disease (CVD). High-sensitivity cardiac troponin T (hs-cTnT) can detect subclinical myocardial injury in asymptomatic prediabetic patients. We aimed to investigate the relationship between left ventricular (LV) function and hs-cTnT in prediabetic patients. Between 1 October 2021 and 1 October 2022, we recruited 96 prediabetic and an equal number of age- and gender-matched healthy volunteers prospectively. TDI was used to evaluate both systolic and diastolic functions. Hs-cTnT levels were obtained and compared between groups. It was found that the values for mitral annular plane systolic excursion (MAPSE), E, the rapid filling wave, E/Em, and the peak annular velocities of systolic excursion in the ejection period (Sm) were all significantly higher in these patients compared to healthy individuals (p < .001). Hs-cTnT was an independent predictor of left ventricular diastolic dysfunction (LVDD) and left ventricular systolic dysfunction (LVSD) (odds ratio [OR] = 2.625, 95% confidence interval [CI] = 1.324-4.308, p < .001, and OR = 1.922, 95% CI = 0.454-3.206, p = .004). Prediabetics had higher hs-cTnT levels than controls. We showed that LVSD and LVDD functions were negatively affected in prediabetic patients. Our results proved that hs-cTnT levels may be associated with subclinical LV dysfunction in prediabetes.
- 17 June 2024
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 79 (6) , 699-704
Association of high-sensitivity troponin T with left ventricular dysfunction in prediabetes
Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are an increasingly serious problem worldwide. Tissue Doppler imaging (TDI), a non-invasive technique, may evaluate both systolic and diastolic function during the first phases of cardiovascular disease (CVD). High-sensitivity cardiac troponin T (hs-cTnT) can detect subclinical myocardial injury in asymptomatic prediabetic patients. We aimed to investigate the relationship between left ventricular (LV) function and hs-cTnT in prediabetic patients. Between 1 October 2021 and 1 October 2022, we recruited 96 prediabetic and an equal number of age- and gender-matched healthy volunteers prospectively. TDI was used to evaluate both systolic and diastolic functions. Hs-cTnT levels were obtained and compared between groups. It was found that the values for mitral annular plane systolic excursion (MAPSE), E, the rapid filling wave, E/Em, and the peak annular velocities of systolic excursion in the ejection period (Sm) were all significantly higher in these patients compared to healthy individuals (p < .001). Hs-cTnT was an independent predictor of left ventricular diastolic dysfunction (LVDD) and left ventricular systolic dysfunction (LVSD) (odds ratio [OR] = 2.625, 95% confidence interval [CI] = 1.324-4.308, p < .001, and OR = 1.922, 95% CI = 0.454-3.206, p = .004). Prediabetics had higher hs-cTnT levels than controls. We showed that LVSD and LVDD functions were negatively affected in prediabetic patients. Our results proved that hs-cTnT levels may be associated with subclinical LV dysfunction in prediabetes.
- Open Access
- 14 June 2024
- Published by Gaziantep Islam Science and Technology University in Experimental and Applied Medical Science
- Vol. 5 (2) , 22-35
The Application of Artificial Intelligence in the Field of Cardiovascular Diseases Focuses on Both Diagnostic and Therapeutic Aspects.
Artificial intelligence (AI) is used in the field of medicine to retrieve information from large databases by using advanced computer algorithms. AI has the potential to accelerate the identification and management of cardiovascular diseases (CVDs), including conditions such as heart failure, atrial fibrillation, valvular heart disease, hypertrophic cardiomyopathy, congenital heart disease, and several others. From a clinical perspective, AI enhances the diagnosis of CVD, increases the usefulness of auxiliary tools, aids in stratifying and identifying different types of diseases, and enables accurate prediction of outcomes. State-of-the-art AI algorithms, designed to extract minute connections from extensive healthcare data, are anticipated to address more challenging tasks compared to earlier methods. The goal of this research is to emphasize the current uses of AI in CVDs, thereby equipping doctors with little knowledge in computer science to gain a deeper understanding and effectively use AI algorithms in clinical practice.
- 14 June 2024
- Published by Gaziantep Islam Science and Technology University in Experimental and Applied Medical Science
- Vol. 5 (2) , 22-35
Open AccessThe Application of Artificial Intelligence in the Field of Cardiovascular Diseases Focuses on Both Diagnostic and Therapeutic Aspects.
Artificial intelligence (AI) is used in the field of medicine to retrieve information from large databases by using advanced computer algorithms. AI has the potential to accelerate the identification and management of cardiovascular diseases (CVDs), including conditions such as heart failure, atrial fibrillation, valvular heart disease, hypertrophic cardiomyopathy, congenital heart disease, and several others. From a clinical perspective, AI enhances the diagnosis of CVD, increases the usefulness of auxiliary tools, aids in stratifying and identifying different types of diseases, and enables accurate prediction of outcomes. State-of-the-art AI algorithms, designed to extract minute connections from extensive healthcare data, are anticipated to address more challenging tasks compared to earlier methods. The goal of this research is to emphasize the current uses of AI in CVDs, thereby equipping doctors with little knowledge in computer science to gain a deeper understanding and effectively use AI algorithms in clinical practice.